



Silencing of *HOTAIR* Induced Apoptosis in Human Colorectal Cancer Cells through Up-regulation of *Bax* and Down-regulation of *Bcl2*

Reza Dashtbozorgi ^{1,2}, Maryam Tahmasebi-Birgani ^{3,*}, Mohammad-Reza Hajjari⁴ and Amirnader Emami Razavi⁵

¹Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

²Department of Biology, Faculty of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran

³Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

⁴Department of Genetics, Faculty of Sciences, Shahid Chmaran University of Ahvaz, Ahvaz, Iran

⁵Iran National Tumor Bank, Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding author: Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: maryam_tahmaseby@yahoo.com

Received 2021 June 04; Revised 2021 October 02; Accepted 2021 October 11.

Abstract

HOX transcript antisense RNA (*HOTAIR*), as a long noncoding RNA (lncRNA) is a highly cited transcript modulating variety of signaling pathways such as cell growth and apoptosis. Altered expression of *HOTAIR* has been reported in human cancers, which contributes with cancer progression and metastasis. Increased expression level of *HOTAIR* has been observed in colorectal cancer (CRC). It seems that dysregulation of *HOTAIR* may inhibit the apoptosis. The present study was aimed to evaluate the effect of *HOTAIR* silencing on expression of apoptosis markers *Bax* and *Bcl2* using real-time polymerase chain reaction (PCR). The data showed that *HOTAIR* and *Bcl2* are highly expressed in CRC cells while the expression level of *Bax* is low. Following siRNA treatment, *Bcl2* was downregulated but *Bcl2* was upregulated. These findings suggest that *HOTAIR* silencing can promote apoptosis, and thus it can be considered as a promising strategy to kill cancer cells.

Keywords: Colorectal Cancer, Apoptosis, Long Noncoding RNA, *HOTAIR*, *Bax*, *Bcl2*

1. Background

Colorectal cancer (CRC) has been recorded as one of the global top 10 cancers allocating rank four after skin, lung, and breast (1, 2). In 2017, 1.8 million incident cases of CRC along with 896000 deaths were reported. CRC is more prevalent in men than women (1/26 for men vs. 1/40 for women) (3, 4). Family history of the disease, inflammatory bowel disease, obesity, and alcohol and tobacco consumption are well-documented risk factors of CRC (5-7). Although this type of cancer has mostly been observed in adults, CRC has been diagnosed at any age (8). Dysregulation of genes may affect the cellular behavior and promote tumorigenesis (9, 10). Long noncoding RNAs (lncRNAs) are lengthy non-protein coding transcripts which are actively involved in modulating critical cellular signaling pathways containing cell cycle, apoptosis, and differentiation (11, 12). Abnormal expression levels of lncRNAs have been described in different human tumors (13). HOX transcript antisense RNA (*HOTAIR*) is one of the well-studied lncRNAs which has been dysregulated in a variety of solid tumors (13, 14). The literature demonstrated that *HOTAIR* is

associated with apoptosis. Increased expression of *HOTAIR* may suppress apoptosis (15, 16)]. Gene silencing through RNA interference (RNAi) strategy is recently suggested as the therapeutic method against cancer (17, 18). This is a non-invasive approach which can effectively target the critical pathways of cell proliferation, growth, or invasion (19).

2. Objectives

The present study aimed to investigate the effect of *HOTAIR* silencing in triggering apoptosis through targeting *Bax* and *Bcl2* in cellular model of CRC.

3. Methods

3.1. Cell Lines/Culture Condition

The cellular model of CRC Caco-2 was purchased from the national cell bank of the Pasteur Institute, Tehran, Iranian Biological Resource Center. Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Life Technologies, USA) containing 2mM Glutamine, 10% FBS, 1% peni-

cillin, and 1% streptomycin (Life Technologies, USA). Cells were incubated at 37°C and atmosphere of 5% CO₂.

3.2. HOTAIR siRNA Transfection

The 3×10^4 cells were plated onto the 6-well plates and treated with 50 nM siRNA duplexes (siHOTAIR I, SASI Hs02 00380445) for 48h using Lipofectamine™ 2000 (Invitrogen, USA) according to the user guideline. Concentration of siRNA was set based on the concentration in our pilot research, and found this concentration more suitable for knocking out. MISSION® siRNA Universal Negative Control #1, SIGMA/SIC001) was used as negative control (20). The mock test was defined as cells treated with lipofectamine and without siRNA.

3.3. RNA Extraction and Real-Time Polymerase Chain Reaction

Following 48h of treatment with siRNA, total RNA was extracted from transfected cells using Trizol reagent (Invitrogen, USA) based on manufacturer protocol. The RNAs were reverse transcribed to cDNA through Primer-Script one step real-time polymerase chain reaction (RT-PCR) kit (Biofact). The cDNA samples were amplified using the SYBR green kit (Biofact) during real-time PCR. The primers used in this study are listed in Table 1. Relative gene expression was calculated as $2^{-\Delta\Delta Ct}$.

3.4. Statistical Analyses

Data were analyzed using a one-way analysis of variance with Newman-Keuls correction for multiple comparisons using the GraphPad Prism version 6 (GraphPad Software, USA). The nonparametric tests were used if normal distribution was not met. P-value less than 0.05 was considered as a statistically significant difference.

4. Results

As illustrated in Figure 1 HOTAIR is strongly expressed in normal culture of Caco-2 cells before siRNA treatment. However, its expression level has been significantly down-regulated since the HOTAIR-specific siRNA was added into the culture medium. The fold-change was 0.06 ± 0.011 (P-value < 0.001).

In the same way, the expression level of Bcl2 was high in normal culture of Caco-2 and downregulated after 48 h of treatment with HOTAIR-specific siRNA. The corresponding fold-change was 0.26 ± 0.042 (P-value < 0.001) (Figure 2). Conversely, the expression level of Bax was weak in Caco-2 cells and significantly increased as the cells were treated with HOTAIR-siRNA. The calculated fold-change was 4.6 ± 0.031 (P-value < 0.001) (Figure 3).




Figure 1. Effects of HOTAIR specific siRNA on suppressing HOTAIR transcript after treatment with 50 ng siRNA after 48 hours of treatment. Data expressed as mean \pm standard deviation (the stars *** show the P-value less than 0.001 compared to the control group).

5. Discussion

The present study showed the effects of HOTAIR silencing on the induction of apoptosis. Two well-known modulators of apoptosis, Bax, and Bcl2, were traced. Data showed Increased expression of Bax and decreased expression of Bcl2. Previously studies indicated that inhibition of HOTAIR can promotes apoptosis through different signaling pathways. However, the underlying mechanism is not well-understood in CRC. The Bax protein, which is a pro-apoptosis factor, activates apoptosis, while the Bcl2 is an anti-apoptotic protein. The Bax/Bcl2 ratio acts as a controller which decides whether cells turn on apoptosis or not. At the lower levels of ratio, the apoptosis is suppressed (21). Similarly, previous studies showed the high expression of Bcl2 in different cancers, which made them resistant to chemo- or radio-therapy (22). This is the reason that the oncoprotein Bcl2 has been proposed as therapeutic target for cancer through apoptosis induction (23). We also found that Bax had low level of expression, and its expression increased around 4-fold following siRNA treatment. The low expression of this gene was previously reported in colorectal and lung cancers (24, 25). It has been demonstrated that Bax permeabilizes the mitochondrial membrane to release cytochrome c and eventually apoptosis (26). Therefore, agents that activate Bax can be considered as promising anticancer drug. Several drugs have

Table 1. Used Primers in This Study

Target Gene	Sequence Primer	Amplicon Length
<i>HOTAIR</i>	F:AGGCCCTGCCTTCTGCCT	147 bp
	R:TGCTCTTACCCACGGA	
<i>BAX</i>	F:TTCATCCAGGATCGAGCAGG	103 bp
	R:TGAGACACTCGCTCAGCTTC	
<i>BCL2</i>	F:GAGGATTGTGGCTTCTTTG	143 bp
	R:CGTATCCTGGATCCAGGTG	
<i>GAPDH</i>	F:GTGAACCATGAGAAGTATGACAAC	123bp
	R:CATGAGTCCTCCACGATACC	




Figure 2. *HOTAIR* specific siRNA effects on suppressing *Bcl2* transcript after treatment with 50 ng *HOTAIR*-siRNA after 48 hours of treatment. Data expressed as mean \pm standard deviation (the stars *** show the P-value less than 0.001 compared to the control group).




Figure 3. *HOTAIR* specific siRNA effects on suppressing *Bax* transcript after treatment with 50 ng *HOTAIR*-siRNA after 48 hours of treatment. Data expressed as mean \pm standard deviation (***) $P < 0.001$ compared to control; the stars *** show the P-value less than 0.001 compared to the control group).

been confirmed or candidate to activate *Bax* directly or indirectly. Bortezomib, Ixabepilone, and Sorafenib are three examples of *Bax* activators (26). In conclusion, high level of *Bcl2* protein and low level of *Bax* can inhibit apoptosis in cancer cells, while low amount of *Bcl2* and high amount of *Bax* make cancer cells susceptible to the apoptosis. As we observed here, *HOTAIR* silencing can act as apoptosis inducer, which is partly due to the activation of *Bax* and in-

hibition of *Bcl2*. It would be ideal to consider the growth inhibitory effect of *HOTAIR* silencing on mouse models for CRC. Such a study might clarify whether *HOTAIR* silencing can provide a promising strategy to cure cancers. It is necessary to remind that apoptosis is only one among hundreds of molecular pathways under the control of *HOTAIR*. This lengthy noncoding transcript regulates variety of cellular pathways, including cell cycle, differentiation, and

growth (27). Therefore, HOTAIR silencing may inhibit the cancer progression through different pathways, which can be considered in future studies.

Acknowledgments

This manuscript has been extracted from the MSc thesis registered in the Faculty of Basic Sciences, Islamic Azad University, Science and Research Branch, Tehran, Iran (this study was ethically approved in IRD1466399). The authors appreciate all colleagues at Cellular and Molecular Research Center for their immeasurable supports during this project.

Footnotes

Authors' Contribution: Study concept and design, R. D.; Analysis and interpretation of data, R. D., and M. T. and M. H.; Drafting of the manuscript, R. D., and M. T. and M. H.; Critical revision of the manuscript for important intellectual content, M. T., M. H., and A. E.; Study supervision, M. T. and M. H.

Conflict of Interests: The authors declare no conflict of interest.

Funding/Support: The project was financially supported by personal cost of Reza Dashtbozorgi and experimentally performed at Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

References

- Vinson KE, George DC, Fender AW, Bertrand FE, Sigounas G. The Notch pathway in colorectal cancer. *Int J Cancer*. 2016;**138**(8):1835–42. doi: [10.1002/ijc.29800](https://doi.org/10.1002/ijc.29800). [PubMed: [26264352](https://pubmed.ncbi.nlm.nih.gov/26264352/)].
- Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi RE, Corcione F. Worldwide burden of colorectal cancer: A review. *Updates Surg*. 2016;**68**(1):7–11. doi: [10.1007/s13304-016-0359-y](https://doi.org/10.1007/s13304-016-0359-y). [PubMed: [27067591](https://pubmed.ncbi.nlm.nih.gov/27067591/)].
- Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F; Global Burden of Disease Cancer Collaboration, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. *JAMA Oncol*. 2019;**5**(12):1749–68. doi: [10.1001/jamaoncol.2019.2996](https://doi.org/10.1001/jamaoncol.2019.2996). [PubMed: [31560378](https://pubmed.ncbi.nlm.nih.gov/31560378/)]. [PubMed Central: [PMC6777271](https://pubmed.ncbi.nlm.nih.gov/PMC6777271/)].
- GBD Colorectal Cancer Collaborators. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol*. 2019;**4**(12):913–33. doi: [10.1016/S2468-1253\(19\)30345-0](https://doi.org/10.1016/S2468-1253(19)30345-0). [PubMed: [31648977](https://pubmed.ncbi.nlm.nih.gov/31648977/)]. [PubMed Central: [PMC7026697](https://pubmed.ncbi.nlm.nih.gov/PMC7026697/)].
- Salehiniya H, Pouyesh V, Tarazoj AA, Mohammadian-Hafshejani A, Aghajani M, Yousefi SM, et al. Colorectal cancer in the world: incidence, mortality and risk factors. *Biomed Res Ther*. 2017;**4**(10):1656. doi: [10.15419/bmrat.v4i10.372](https://doi.org/10.15419/bmrat.v4i10.372).
- Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. *Prz Gastroenterol*. 2019;**14**(2):89–103. doi: [10.5114/pg.2018.81072](https://doi.org/10.5114/pg.2018.81072). [PubMed: [31616522](https://pubmed.ncbi.nlm.nih.gov/31616522/)]. [PubMed Central: [PMC6791134](https://pubmed.ncbi.nlm.nih.gov/PMC6791134/)].
- Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Meta-analyses of colorectal cancer risk factors. *Cancer Causes Control*. 2013;**24**(6):1207–22. doi: [10.1007/s10552-013-0201-5](https://doi.org/10.1007/s10552-013-0201-5). [PubMed: [23563998](https://pubmed.ncbi.nlm.nih.gov/23563998/)]. [PubMed Central: [PMC4161278](https://pubmed.ncbi.nlm.nih.gov/PMC4161278/)].
- Lee K. *Measuring factors affecting colorectal cancer screening behavior and preference for colorectal cancer screening tests using the health belief model and a conjoint analysis [master's thesis]*. Goyang, South Korea: National Cancer Center Graduate School of Cancer Science and Policy; 2019.
- Zoratto F, Rossi L, Verrico M, Papa A, Basso E, Zullo A, et al. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: Implications for molecular diagnosis. *Tumour Biol*. 2014;**35**(7):6195–206. doi: [10.1007/s13277-014-1845-9](https://doi.org/10.1007/s13277-014-1845-9). [PubMed: [25051912](https://pubmed.ncbi.nlm.nih.gov/25051912/)].
- Okugawa Y, Grady WM, Goel A. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. *Gastroenterology*. 2015;**149**(5):1204–1225 e12. doi: [10.1053/j.gastro.2015.07.011](https://doi.org/10.1053/j.gastro.2015.07.011). [PubMed: [26216839](https://pubmed.ncbi.nlm.nih.gov/26216839/)]. [PubMed Central: [PMC4589488](https://pubmed.ncbi.nlm.nih.gov/PMC4589488/)].
- Hauptman N, Glavac D. Long non-coding RNA in cancer. *Int J Mol Sci*. 2013;**14**(3):4655–69. doi: [10.3390/ijms14034655](https://doi.org/10.3390/ijms14034655). [PubMed: [23443164](https://pubmed.ncbi.nlm.nih.gov/23443164/)]. [PubMed Central: [PMC3634483](https://pubmed.ncbi.nlm.nih.gov/PMC3634483/)].
- Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: A new player in cancer. *J Hematol Oncol*. 2013;**6**:37. doi: [10.1186/1756-8722-6-37](https://doi.org/10.1186/1756-8722-6-37). [PubMed: [23725405](https://pubmed.ncbi.nlm.nih.gov/23725405/)]. [PubMed Central: [PMC3693878](https://pubmed.ncbi.nlm.nih.gov/PMC3693878/)].
- Zhai N, Xia Y, Yin R, Liu J, Gao F. A negative regulation loop of long noncoding RNA HOTAIR and p53 in non-small-cell lung cancer. *Onco Targets Ther*. 2016;**9**:5713–20. doi: [10.2147/OTT.S110219](https://doi.org/10.2147/OTT.S110219). [PubMed: [27695348](https://pubmed.ncbi.nlm.nih.gov/27695348/)]. [PubMed Central: [PMC5033503](https://pubmed.ncbi.nlm.nih.gov/PMC5033503/)].
- Angelopoulou E, Paudel YN, Piperi C. Critical role of HOX transcript antisense intergenic RNA (HOTAIR) in gliomas. *J Mol Med (Berl)*. 2020;**98**(11):1525–46. doi: [10.1007/s00109-020-01984-x](https://doi.org/10.1007/s00109-020-01984-x). [PubMed: [32978667](https://pubmed.ncbi.nlm.nih.gov/32978667/)].
- Qu X, Alsager S, Zhuo Y, Shan B. HOX transcript antisense RNA (HOTAIR) in cancer. *Cancer Lett*. 2019;**454**:90–7. doi: [10.1016/j.canlet.2019.04.016](https://doi.org/10.1016/j.canlet.2019.04.016). [PubMed: [30981759](https://pubmed.ncbi.nlm.nih.gov/30981759/)].
- Wu Y, Zhang L, Zhang L, Wang Y, Li H, Ren X, et al. Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma. *Int J Oncol*. 2015;**46**(6):2586–94. doi: [10.3892/ijo.2015.2976](https://doi.org/10.3892/ijo.2015.2976). [PubMed: [25901533](https://pubmed.ncbi.nlm.nih.gov/25901533/)].
- Zhu KY, Palli SR. Mechanisms, Applications, and Challenges of Insect RNA Interference. *Annu Rev Entomol*. 2020;**65**:293–311. doi: [10.1146/annurev-ento-011019-025224](https://doi.org/10.1146/annurev-ento-011019-025224). [PubMed: [31610134](https://pubmed.ncbi.nlm.nih.gov/31610134/)].
- Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. *Cancer Metastasis Rev*. 2018;**37**(1):107–24. doi: [10.1007/s10555-017-9717-6](https://doi.org/10.1007/s10555-017-9717-6). [PubMed: [29243000](https://pubmed.ncbi.nlm.nih.gov/29243000/)]. [PubMed Central: [PMC5898634](https://pubmed.ncbi.nlm.nih.gov/PMC5898634/)].
- Abdelrahim M, Safe S, Baker C, Abudayyeh A. RNAi and cancer: Implications and applications. *J RNAi Gene Silencing*. 2006;**2**(1):136–45. [PubMed: [19771215](https://pubmed.ncbi.nlm.nih.gov/19771215/)]. [PubMed Central: [PMC2737210](https://pubmed.ncbi.nlm.nih.gov/PMC2737210/)].
- Tang L, Zhang W, Su B, Yu B. Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma. *Biomed Res Int*. 2013;**2013**:251098. doi: [10.1155/2013/251098](https://doi.org/10.1155/2013/251098). [PubMed Central: [PMC3687722](https://pubmed.ncbi.nlm.nih.gov/PMC3687722/)].
- Khodapasand E, Jafarzadeh N, Farrokhi F, Kamalidehghan B, Houshmand M. Is Bax/Bcl-2 ratio considered as a prognostic marker with age and tumor location in colorectal cancer? *Iran Biomed J*. 2015;**19**(2):69–75. doi: [10.6091/ibj.1366.2015](https://doi.org/10.6091/ibj.1366.2015). [PubMed: [25864810](https://pubmed.ncbi.nlm.nih.gov/25864810/)]. [PubMed Central: [PMC4412916](https://pubmed.ncbi.nlm.nih.gov/PMC4412916/)].

22. Ghasemi A, Khanzadeh T, Zadi Heydarabad M, Khorrami A, Jahanban Esfahlan A, Ghavipankeh S, et al. Evaluation of BAX and BCL-2 Gene Expression and Apoptosis Induction in Acute Lymphoblastic Leukemia Cell Line CCRFCEM after High- Dose Prednisolone Treatment. *Asian Pac J Cancer Prev*. 2018;**19**(8):2319–23. doi: [10.22034/APJCP.2018.19.8.2319](https://doi.org/10.22034/APJCP.2018.19.8.2319). [PubMed: [30141309](https://pubmed.ncbi.nlm.nih.gov/30141309/)]. [PubMed Central: [PMC6171400](https://pubmed.ncbi.nlm.nih.gov/PMC6171400/)].
23. Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. *Open Biol*. 2018;**8**(5). doi: [10.1098/rsob.180002](https://doi.org/10.1098/rsob.180002). [PubMed: [29769323](https://pubmed.ncbi.nlm.nih.gov/29769323/)]. [PubMed Central: [PMC5990650](https://pubmed.ncbi.nlm.nih.gov/PMC5990650/)].
24. Aoyagi T, Morii T, Ohtsuka K, Ohnishi H, Tajima T, Yoshiyama A, et al. Lung cancer cell line sensitivity to Zoledronic acid is BAX-dependent. *Anticancer Res*. 2013;**33**(12):5357–63. [PubMed: [24324070](https://pubmed.ncbi.nlm.nih.gov/24324070/)].
25. Manoochehri M, Karbasi A, Bandehpour M, Kazemi B. Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer. *Pathol Oncol Res*. 2014;**20**(2):301–7. doi: [10.1007/s12253-013-9695-0](https://doi.org/10.1007/s12253-013-9695-0). [PubMed: [24122668](https://pubmed.ncbi.nlm.nih.gov/24122668/)].
26. Liu Z, Ding Y, Ye N, Wild C, Chen H, Zhou J. Direct Activation of Bax Protein for Cancer Therapy. *Med Res Rev*. 2016;**36**(2):313–41. doi: [10.1002/med.21379](https://doi.org/10.1002/med.21379). [PubMed: [26395559](https://pubmed.ncbi.nlm.nih.gov/26395559/)]. [PubMed Central: [PMC4752390](https://pubmed.ncbi.nlm.nih.gov/PMC4752390/)].
27. Hajjari M, Rahnama S. Association Between SNPs of Long Non-coding RNA HOTAIR and Risk of Different Cancers. *Front Genet*. 2019;**10**:113. doi: [10.3389/fgene.2019.00113](https://doi.org/10.3389/fgene.2019.00113). [PubMed: [30873206](https://pubmed.ncbi.nlm.nih.gov/30873206/)]. [PubMed Central: [PMC6403183](https://pubmed.ncbi.nlm.nih.gov/PMC6403183/)].